Researchers employed an extensive analysis of genomic information to identify a new, high-risk cohort of ovarian cancer patients, characterize their tumors, find a potential treatment and test it in mouse models of the disease.
The exhaustive analysis that led to micro RNA 506 (miR-506) as a potential therapeutic candidate for advanced or metastatic ovarian cancer is the cover article in the Feb. 11 edition of Cancer Cell.
“Functional analysis showed that miR-506 is a robust inhibitor of a cellular transition that makes ovarian cancer cells more resistant to treatment and likely to spread. We will continue to investigate this micro RNA as an inhibitor of ovarian cancer metastasis,” said Wei Zhang, Ph.D. professor in MD Anderson’s Department of Pathology and senior author of the paper.
Micro RNAs do not code for genes like their cousins, the messenger RNAs. They are capable of blocking a gene’s activation by plugging up its promoter region or altering its protein after it’s expressed.
Cell line experiments demonstrated that miR-506 blocks cancer cells by suppressing a protein crucial to transforming a cell from one type to another associated with cancer invasiveness, metastasis and shortened survival.
Analysis of human tumors showed higher miR-506 expression is associated with longer overall survival. Mice with two types of advanced ovarian cancer treated with miR-506 packaged in a fatty (liposomal) nanoparticle had fewer and smaller tumors than control mice.
“We next plan to test whether miR-506 sensitizes ovarian cancer cells to cisplatin (standard chemotherapy) in our mouse model,” Zhang said.
The liposomal nanoparticles already have been shown to be safe for human use, said co-senior author Anil Sood, M.D., professor in MD Anderson’s Departments of Gynecologic Oncology and Cancer Biology and the Center for RNAi and Non-Coding RNA. “After the additional combination experiments, we would need to do formal safety testing before moving it into clinical trials,” Sood said.
Ovarian cancer is the most lethal gynecologic cancer in the United States, with an estimated 22,280 cases diagnosed in 2012 and 15,460 deaths. Ovarian cancer is often diagnosed at an advanced stage and it also has greater capacity to spread than most other solid tumors.
New analysis of The Cancer Genome Atlas data
Based on gene expression data from 489 high-grade serous ovarian carcinoma patients, TCGA’s initial study published in Nature divided these patients into four categories but found no survival differences among the groups.
Zhang, who is co-director of a TCGA genomics center, and colleagues applied additional analyses to better understand the TCGA category of mesenchymal ovarian cancer. Most solid tumors are carcinomas, meaning that they start in the lining (epithelium) of the organ. Emerging evidence, Zhang noted, connects ovarian cancer cell invasiveness and spread to a loss of epithelial features and a gain of mesenchymal features, known as epithelial to mesenchymal transition.
There are a number of significant differences between the two types of cell. One is mobility: epithelial cells are designed to stay put and are likely to die in a variety of ways if they break away from the primary tumor. Mesenchymal cells can move about. They also rely on distinctive protein biomarkers.
The search narrows, from 2,942 genes to one miRNA
The researchers used additional data from the TCGA group – alterations of gene copy number, miRNA expression and DNA methylation, which silences genes – and re-analyzed the 489 patients.
“With those data, we were able to identify a subtype of ovarian cancer, look deeply into the mechanism behind it and identify regulators of that type so we can develop new treatments,” said co-lead author Da Yang, Ph.D., an MD Anderson Odyssey Scholar in the pathology department.
Starting with 2,942 genes that TCGA identified as overexpressed in the mesenchymal group, they narrowed that list to 253 genes, 219 of which were associated with miRNA.
They found that the 219 miRNA-associated mesenchymal genes divided 455 ovarian cancer patients into two clusters:
- 171 with high levels of miRNA expression, 169 of whom had high-grade disease, and shorter survival, classified as the mesenchymal subtype.
- 284 with low levels of miRNA gene expression, longer survival and lower grade disease, classified as the epithelial subtype.
The team confirmed these results in three independent data sets totaling 560 ovarian cancer patients.
Nineteen miRNAs were identified, eight of which were predicted to control 89 percent of the 219 miRNA-associated genes. Of the eight, the least was known about miR-506, and it was least expressed in the mesencyhmal cases. “We decided to focus on miR-506,” Zhang said.
miR-506 blocks mesenchymal, helps epithelial proteins
In a series of cell line experiments, the scientists forced overexpression of miR-506 and a control miRNA in ovarian cancer cells. Treated cells had much lower levels of two important mesenchymal markers and higher levels of E-cadherin, a protein vital to epithelial cells.
Additional experiments showed miR-506 specifically inhibited SNAI2, a mesenchymal-cell-promoting protein, by binding to the promoter region of its gene, blocking activation.
Transforming growth factor beta (TGFß) induces epithelial-to-mesenchymal cell transition, and the team found that it was prominent in the mesenchymal type of ovarian cancer. In cancer cells treated with miR-506 and then treated with TGFß, the miRNA completely abolished TGFß’s effects.
In human tumors, more miR-506 tied to improved survival
Analysis of 92 ovarian cancer tumors from Tianjin Hospital in Tianjin, China, showed:
- Tumors with low levels of miR-506 had mesenchymal traits, including high levels of SNAI2 and VIM, another mesenchymal biomarker, and low levels of E-cadherin.
- Tumors with high levels of miR-506 had epithelial traits, including more E-cadherin, and less SNAI2 and VIM.
- High miR-506 Tianjin patients had a median survival of 50 months, compared with 30 months for those with low levels.
These results were repeated in two separate data sets of 160 cases.
Zhang and colleagues treated mice with two ovarian cancer cell lines with either nanoparticle miR-506 or a control nanoparticle.
Mice treated with miR-506 not only had fewer (75 and 48 percent declines), smaller tumors (down 78 and 53 percent), they also had steeply reduced levels of SNAI2 and VIM and major boosts of E-cadherin (200 and 120 percent increases).
These results suggest liposomal nanoparticle-delivered miR-506 might be developed as an ovarian cancer treatment. While miRNA has been effective in lab experiments, delivery in liposomal nanoparticles has shown promise in research at MD Anderson and other institutions.
Longstanding collaborations with the Institute for Systems Biology in Seattle, and MD Anderson sister institution Tianjin Medical University are vital to this research, Zhang said.
Co-authors with Zhang, Sood and Yang are co-lead authors, Yan Sun, M.D., PhD, and Limei Hu, MD, Ping Ji, PhD, Hanyin Cheng, PhD., David Cogdell, MS, Russell Broaddus, MD, PhD, Jinsong Liu, MD, PhD. of MD Anderson’s Department of Pathology; Cristian Rodriguez-Aguayo, PhD, Gabriel Lopez-Berestein, MD MD Anderson Department of Experimental Therapeutics; co-lead author Hong Zheng, Yanrui Zhao, and Kexin Chen, MD, PhD. Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Chad Pecot, M.D. MD Anderson’s Department of Thoracic/Head and Neck Oncology; Sheila Reynolds, Ph.D., and Ilya Shmulevich, Ph.D., Institute for Systems Biology, Seattle; Rajesha Rupaimoole, MD Anderson’s Department of Gynecologic Oncology and Reproductive Medicine; Matti Nykter, PhD, Tampere University of Technology, Tampere, Finland.
This study was supported by grants from the National Cancer Institute of the National Institutes of Health (U24CA143835, U54 CA151668) and the MD Anderson Ovarian Cancer SPORE (P50 CA083639); a grant from the Blanton-Davis Ovarian Cancer Research Program, a Cancer Research Fund Program Project Development grant, the Program for Changjiang Scholars and Innovative Research Team in University in China, National Key Scientific and Technological Project, and Tianjin Science and Technology Committee Foundation grants; the Finnish Funding Agency for Technology and Innovation Finland Distinguished Professor Program.
Genomic studies were supported in part by the Cancer Genomics Core Laboratory and the National Institutes of Health through MD Anderson’s Cancer Center Support Grant (CA016672); The Diane Denson Tobola Fellowship in Ovarian Cancer Research and The Harold C. and Mary L. Daily Endowment Fund; the Natural Science Foundation of China, the Linda K. Manning Fellowship in Ovarian Cancer, and The A. Lavoy Moore Endowment Fund.